Combination therapy in metastatic castration sensitive prostate cancer: A Systematic review and network meta-analysis.

ABSTRACT:

Introduction

Studies directly comparing the different combination therapies offered to men with metastatic castration sensitive prostate cancer (mCSPC), are not available yet. This study was designed using the network meta-analysis (NMA) framework to provide a comparison of the different available options for the treatment of men with mCSPC.

Methods

A systematic search was performed and the prospective randomized controlled trials reporting the overall survival (OS) or failure-free survival (FFS) were selected for review. A total of 14 studies were included in the NMA.

Results

The addition of abiraterone, apalutamide, docetaxel, and docetaxel with zoledronic acid to the androgen deprivation therapy (ADT) demonstrated a significant improvement in the OS. In indirect co

SUBMITTER: Kumar J 

PROVIDER: S-EPMC9380455 | biostudies-literature | 2022 Jul-Sep

REPOSITORIES: biostudies-literature